CD22

 CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins.[5] It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.[6]

CD22
Identifiers
AliasesCD22, SIGLEC-2, SIGLEC2, CD22 molecule
External IDsOMIM107266 MGI88322 HomoloGene31052 GeneCardsCD22
Gene location (Human)
Chromosome 19 (human)
Chr.Chromosome 19 (human)[1]
Chromosome 19 (human)
Genomic location for CD22
Genomic location for CD22
Band19q13.12Start35,319,261 bp[1]
End35,347,361 bp[1]
RNA expression pattern
PBB GE CD22 204581 at fs.png

PBB GE CD22 217422 s at fs.png

PBB GE CD22 38521 at fs.png
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001043317
NM_009845

RefSeq (protein)

NP_001172028
NP_001172029
NP_001172030
NP_001265346
NP_001762

NP_001036782
NP_033975

Location (UCSC)Chr 19: 35.32 – 35.35 MbChr 7: 30.87 – 30.88 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.[7]

As a drug targetEdit

An immunotoxin, BL22, that targets this receptor is being tested at the NIH.[8]

As a treatment for acute lymphoblastic leukemia (ALL), Inotuzumab ozogamicin is an antibody-drug conjugate that targets this molecule.

InteractionsEdit

CD22 has been shown to interact with Grb2,[9][10] PTPN6,[10][11][12][13][14] LYN,[9][12] SHC1[9] and INPP5D.[9]

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License
.